Glucagon-Like Peptide-1 (GLP-1) agonist medications, like semaglutide, are injectable or oral drugs that mimic the natural GLP-1 hormone, which helps regulate insulin levels. Thus, these medicines help control blood sugar in people with Type 2 diabetes and promote substantial weight loss for individuals with a high body mass index (BMI) by slowing digestion, reducing appetite, and increasing insulin release. But can they also ease symptoms in people with ME/CFS and identify disease subtypes?
Solve Ramsay Research Grant Program alum Dr. Carmen Scheibenbogen (acting director of the Institute for Medical Immunology of the Charité University Hospital in Berlin) recently received a Solve ME/CFS Catalyst Award for her study evaluating whether semaglutide reduces symptoms and improves quality of life for people with ME/CFS who have high BMI.
In this free educational webinar hosted by Solve Chief Scientific Officer Dr. Sadie Whittaker and VP of Scientific Programs Dr. Jessica Maya, Dr. Scheibenbogen discusses details of her study, explains how her research will identify biomarkers, and discusses how these results could help determine which patients are most likely to benefit from treatment.
Watch the webinar recording here.
Review Dr. Scheibenbogen’s presentation deck here.
For viewers interested in learning more, an additional resource mentioned during the webinar that further explores GLP-1 micro-dosing can be found here.